AOD9604 10mg – Fat Metabolism & Metabolic Research Peptide

AOD9604 Description

AOD9604 is a synthetic peptide created from a specific fragment of the human growth hormone molecule.

It is studied for its ability to promote the breakdown of stored fat in the body. Unlike the full growth hormone, it does not stimulate growth or increase levels of IGF-1.

In fat cells, it activates processes that release fats for energy production while reducing the formation of new fat.

Animal studies in obese models have shown reductions in body weight and fat accumulation with its administration.

Human clinical trials involving hundreds of overweight adults have demonstrated that it is safe and well tolerated.

Some early trials reported modest reductions in body weight and abdominal fat.

Larger studies that included diet and exercise programs showed more variable results for weight loss.

Researchers have also investigated its potential to support cartilage repair in joint disease models.

Overall, AOD9604 offers a targeted way to address fat metabolism and certain regenerative applications without the broader effects of complete growth hormone.

Molecular Mechanism of Action

AOD9604, also known as the hexadecapeptide Tyr-hGH177-191, represents a precisely engineered fragment of the carboxyl terminus of human growth hormone (hGH), specifically residues 177 through 191 with an added N-terminal tyrosine residue for enhanced stability and oral bioavailability potential.

This structural modification isolates the lipolytic domain while eliminating the domains responsible for somatotropic, lactogenic, and diabetogenic activities inherent to the full-length 191-amino-acid hGH protein.

In the context of peptide research and synthesis, AOD9604 exemplifies a rational design strategy to dissect multifunctional proteins into bioactive minimal motifs, allowing selective modulation of adipose tissue metabolism without engaging the classical growth hormone receptor (GHR) signaling cascade that leads to JAK2/STAT5 activation and subsequent IGF-1 transcription in hepatocytes and other tissues.

At the biochemical level, this peptide maintains a compact conformation stabilized by a disulfide bridge between the two cysteine residues within its sequence, preserving key hydrophobic and charged motifs that interact with intracellular targets in adipocytes and hepatocytes.

Lipolysis and Fat Metabolism Pathways

The molecular mechanism of action of AOD9604 centers on direct and selective enhancement of lipolysis coupled with potent inhibition of lipogenesis in white adipose tissue, operating largely independently of the somatotropic axis.

In mature adipocytes, triglycerides stored in lipid droplets are hydrolyzed by hormone-sensitive lipase (HSL), the rate-limiting enzyme whose activity is tightly regulated by phosphorylation at multiple serine residues.

AOD9604 elevates intracellular cyclic AMP (cAMP) levels, likely through modulation of adenylate cyclase activity downstream of adrenergic signaling pathways, thereby activating protein kinase A (PKA).

Phosphorylated HSL translocates from the cytosol to the surface of lipid droplets, where it catalyzes the sequential cleavage of triglycerides into:

• diacylglycerol,
• monoacylglycerol,
• free fatty acids,
• and glycerol.

This process is further amplified by upregulation of beta-3 adrenergic receptor (β3-AR) mRNA and protein expression specifically in obese adipose depots, where β3-AR levels are typically downregulated.

Restoration to levels observed in lean tissue heightens catecholamine sensitivity and sustains chronic lipolytic responsiveness without requiring direct agonism at the receptor itself.

Acute effects on energy expenditure and fatty acid oxidation persist even in β3-AR knockout models, indicating parallel or redundant pathways possibly involving direct modulation of mitochondrial β-oxidation enzymes or carnitine palmitoyltransferase-1 (CPT-1) facilitation via reduced malonyl-CoA inhibition.

Anti-Lipogenic and Metabolic Effects

Concomitantly, AOD9604 exerts anti-lipogenic effects by inhibiting acetyl-CoA carboxylase (ACC), the enzyme that carboxylates acetyl-CoA to form malonyl-CoA, the primary substrate for de novo fatty acid synthesis via fatty acid synthase (FAS) and the allosteric inhibitor of CPT-1.

Lower malonyl-CoA concentrations relieve CPT-1 suppression at the outer mitochondrial membrane, channeling free fatty acids into β-oxidation rather than re-esterification or elongation.

This dual lipolytic and anti-lipogenic profile mirrors a subset of hGH actions but occurs without GHR dimerization or downstream PI3K/Akt/mTOR engagement, explaining the absence of IGF-1 induction, muscle anabolism, or hepatic gluconeogenesis.

In hepatocytes, similar ACC inhibition reduces very-low-density lipoprotein (VLDL) triglyceride output, contributing to improved circulating lipid profiles.

At the cellular signaling level, AOD9604 induces a biphasic diacylglycerol (DAG) release that transiently activates protein kinase C (PKC) isoforms, further fine-tuning HSL trafficking and gene expression programs favoring oxidative metabolism over storage.

These mechanisms collectively shift adipocyte metabolism toward net fat mobilization, particularly in visceral depots prone to inflammation and ectopic lipid spillover in metabolic syndrome states.

Unlike full-length hGH, which can induce insulin resistance via SOCS protein upregulation and JAK/STAT-mediated interference with insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation, AOD9604 preserves or may enhance insulin sensitivity by avoiding these feedback loops, as evidenced by maintained euglycemic clamp responses in chronic exposure models.

Potential Research Applications

Potential research applications of AOD9604 extend beyond its original anti-obesity rationale to encompass regenerative applications in orthopedics and metabolic health, leveraging its tissue-selective actions.

In obesity and associated dysmetabolism, the peptide’s ability to target visceral adipose tissue lipolysis without inducing hyperinsulinemia or hyperglycemia positions it as a candidate adjunct for research involving:

• central adiposity,
• non-alcoholic fatty liver disease (NAFLD),
• dyslipidemia,
• and type 2 diabetes risk.

By normalizing β3-AR expression in pathologically desensitized adipocytes, AOD9604 could restore endogenous catecholamine-driven fat mobilization, complementing lifestyle interventions that often fail to sustain visceral fat loss due to adaptive downregulation of lipolytic receptors.

In cartilage biology and osteoarthritis research, intra-articular delivery exploits potential chondroprotective and anabolic effects on synovial and cartilage extracellular matrix remodeling.

Preclinical data indicate:

• enhanced proteoglycan synthesis,
• reduced matrix metalloproteinase activity,
• and improved histological architecture in degenerative joints.

These effects may occur via localized modulation of inflammatory cytokine signaling or direct stimulation of chondrocyte survival pathways independent of systemic GH/IGF-1.

This regenerative profile may extend to bone homeostasis, where osteoblast exposure to the peptide fragment stimulates proliferation and mineralized nodule formation.

This offers utility in postmenopausal osteoporosis models characterized by cortical thinning and reduced bone mineral density.

Collectively, these applications highlight AOD9604 as a versatile tool in peptide-based regenerative and metabolic medicine, capitalizing on its minimal immunogenicity, rapid plasma clearance, and lack of endocrine disruption.

Animal Research Findings

Animal trials have provided robust foundational evidence for these mechanisms and applications across multiple rodent and lagomorph models.

In genetically obese Zucker rats and ob/ob mice, chronic systemic exposure to AOD9604 markedly attenuates excessive body weight gain — by over 50 percent relative to pair-fed controls in some cohorts — through elevated adipose tissue lipolytic rates measured as increased glycerol release ex vivo and heightened whole-body fat oxidation via indirect calorimetry.

These effects correlate with restored β3-AR transcript levels in epididymal and retroperitoneal fat pads, normalizing the lipolytic deficit typical of leptin-resistant states, and occur without the insulin-desensitizing profile observed with equimolar intact hGH.

In β3-AR knockout mice, chronic administration fails to reduce body mass or enhance basal lipolysis, confirming the receptor’s permissive role in sustained adaptations, yet acute bolus dosing still augments energy expenditure and respiratory quotient shifts toward fat utilization, underscoring redundant signaling nodes.

Toxicology assessments in Sprague-Dawley rats and cynomolgus monkeys at supratherapeutic multiples revealed:

• no genotoxicity,
• no organ histopathology,
• no immunogenicity,
• and rapid proteolytic degradation consistent with short plasma half-life.

Cartilage and Bone Research Models

Additional regenerative models reinforce broader utility.

In collagenase-induced knee osteoarthritis in New Zealand white rabbits, repeated intra-articular injections of AOD9604 alone or combined with hyaluronic acid significantly improved:

• macroscopic cartilage surface integrity,
• histological OARSI scores,
• reduced fibrillation,
• reduced chondrocyte clustering,
• reduced proteoglycan loss,
• and functional lameness indices.

These findings suggest matrix-preserving effects potentially mediated by decreased synovial inflammation or upregulated aggrecan and type II collagen expression in chondrocytes.

In ovariectomized rat models of estrogen-deficient bone loss, systemic AOD9604 increased trabecular and cortical bone mineral density, elevated bone formation rates, and preserved biomechanical strength parameters such as ultimate load and stiffness.

These actions are attributed to direct osteoblast mitogenic signaling without osteoclast activation or GH-mediated resorption coupling.

These preclinical outcomes collectively validate selective fat-mobilizing and tissue-reparative properties while highlighting favorable safety margins across species.

Human Clinical Research Findings

Human clinical development encompassed six randomized, double-blind, placebo-controlled trials conducted between 2001 and 2006, enrolling approximately 900 clinically obese adults alongside smaller cohorts of healthy volunteers.

The program progressed from single-dose intravenous and oral pilot studies through short-term multiple-dose evaluations to two pivotal longer-term oral Phase II protocols:

• one 12-week study in roughly 300 participants,
• and one 24-week study in over 500 subjects that incorporated standardized diet and exercise counseling.

Across all protocols, AOD9604 exhibited an adverse event profile statistically indistinguishable from placebo, with mild-to-moderate headaches, transient gastrointestinal discomfort, or upper respiratory symptoms occurring at comparable frequencies.

No treatment-related serious adverse events, withdrawals, or clinically meaningful alterations in vital signs, electrocardiography, hematology, or serum chemistry were reported.

Notably, no increases in circulating IGF-1, perturbations in fasting glucose, insulin, or oral glucose tolerance test parameters, or development of anti-peptide antibodies were detected.

This confirms the absence of somatotropic spillover and supports metabolic neutrality.

Early efficacy signals included modest body weight decrements and preferential abdominal fat reduction assessed by dual-energy X-ray absorptiometry or waist circumference.

However, the larger lifestyle-enriched 24-week trial failed to demonstrate statistically superior weight or fat mass loss relative to placebo plus diet and exercise, leading to discontinuation of further obesity-focused development around 2007 despite the consistently benign safety database.

Subsequent analyses have revisited the dataset for subgroup signals in visceral adiposity responders and have prompted exploratory investigations into intra-articular applications for osteoarthritis, where the peptide’s localized regenerative potential remains under active preclinical-to-early-clinical translation.

Summary

In summary, AOD9604 embodies a successful example of domain-specific peptide engineering that decouples beneficial lipid metabolic reprogramming from the broader effects of parent human growth hormone.

Its molecular actions center on:

• HSL activation,
• ACC inhibition,
• β3-AR sensitization,
• CPT-1 derepression,
• fat mobilization,
• and cartilage-associated regenerative signaling.

These mechanisms drive net adipose catabolism while preserving insulin sensitivity and avoiding endocrine feedback.

Preclinical models support applications in:

• obesity-related fat redistribution,
• joint cartilage preservation,
• skeletal maintenance,
• and metabolic research.

Human experience underscores exceptional tolerability across nearly a thousand exposures.

Although larger-scale weight-loss efficacy proved context-dependent, the peptide’s clean pharmacological footprint and emerging regenerative data sustain interest within specialized peptide research for targeted metabolic and orthopedic applications.

Ongoing synthesis optimization and formulation strategies may further unlock its utility in these domains.